Abstract
| Original language | English |
|---|---|
| Pages (from-to) | 205-214 |
| Number of pages | 10 |
| Journal | Alzheimer's and Dementia |
| Volume | 17 |
| Issue number | 2 |
| Early online date | 2020 |
| DOIs | |
| Publication status | Published - Feb 2021 |
Access to Document
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
Circulating metabolites are associated with brain atrophy and white matter hyperintensities. / de Leeuw, Francisca A.; Karamujić-Čomić, Hata; Tijms, Betty M.; Peeters, Carel F. W.; Kester, Maartje I.; Scheltens, Philip; Ahmad, Shahzad; Vojinovic, Dina; Adams, Hieab H. H.; Hankemeier, Thomas; Bos, Daniel; van der Lugt, Aad; Vernooij, Meike W.; Ikram, M. Arfan; Amin, Najaf; Barkhof, Frederik; Teunissen, Charlotte E.; van Duijn, Cornelia M.; van der Flier, Wiesje M.
In: Alzheimer's and Dementia, Vol. 17, No. 2, 02.2021, p. 205-214.Research output: Contribution to journal › Article › Academic › peer-review
TY - JOUR
T1 - Circulating metabolites are associated with brain atrophy and white matter hyperintensities
AU - de Leeuw, Francisca A.
AU - Karamujić-Čomić, Hata
AU - Tijms, Betty M.
AU - Peeters, Carel F. W.
AU - Kester, Maartje I.
AU - Scheltens, Philip
AU - Ahmad, Shahzad
AU - Vojinovic, Dina
AU - Adams, Hieab H. H.
AU - Hankemeier, Thomas
AU - Bos, Daniel
AU - van der Lugt, Aad
AU - Vernooij, Meike W.
AU - Ikram, M. Arfan
AU - Amin, Najaf
AU - Barkhof, Frederik
AU - Teunissen, Charlotte E.
AU - van Duijn, Cornelia M.
AU - van der Flier, Wiesje M.
N1 - Funding Information: P.S. has received consultancy/speaker fees (paid to the institution) from Novartis, Vivoryon, Genentech, and EIP Pharma. C.T. received grants from the European Commission, the Dutch Research Council (ZonMW), Association of Frontotemporal Dementia/Alzheimer's Drug Discovery Foundation, The Weston Brain Institute, Alzheimer Netherlands. C.T. has a collaboration contract with ADx Neurosciences and performed contract research or received grants from Probiodrug, Biogen, Esai, Toyama, Janssen prevention center, Boehringer, AxonNeurosciences, Fujirebio, EIP farma, PeopleBio, and Roche. Research programs of W.F. have been funded by ZonMW, NWO, EU‐FP7, EU‐JPND, Alzheimer Nederland, CardioVascular Onderzoek Nederland, Health∼Holland, Topsector Life Sciences & Health, stichting Dioraphte, Gieskes‐Strijbis fonds, stichting Equilibrio, Pasman stichting, Biogen MA Inc, Boehringer Ingelheim, Life‐MI, AVID, Roche BV, Janssen Stellar, and Combinostics. W.F. has performed contract research for Biogen MA Inc and Boehringer Ingelheim. W.F. has been an invited speaker at Boehringer Ingelheim and Biogen MA Inc. All funding is paid to her institution. F.B. is a consultant for Biogen‐Idec, Janssen Alzheimer Immunotherapy, Bayer‐Schering, Merck‐Serono, Roche, Novartis, Genzyme, and Sanofi‐Aventis; has received sponsorship from European Commission–Horizon 2020, National Institute for Health Research–University College London Hospitals Biomedical Research Centre, Scottish Multiple Sclerosis Register, TEVA, Novartis, and Toshiba; and serves on the editorial boards of , and . Radiology, Brain, Neuroradiology, Multiple Sclerosis Journal Neurology Funding Information: This work was performed within the framework of the BBMRI Metabolomics Consortium funded by BBMRI‐NL, a research infrastructure financed by the Dutch government (NWO, grant no. 184.021.007 and 184033111). This work is funded by the European Union's Horizon 2020 research and innovation program as part of the Common mechanisms and pathways in Stroke and Alzheimer's disease (CoSTREAM) project ( www.costream.eu , grant agreement No 667375); the European Union Innovative Medicine Initiative (IMI) program under grant agreement No 115975 as part of the Alzheimer Disease Apolipoprotein Pathology for Treatment Elucidation and Development (ADAPTED, https://www.imi-adapted.eu ); and the European Union's Horizon 2020 research and innovation program Marie Skłodowska‐Curie Research and Innovation Staff Exchange (RISE) under the grant agreement No 645740 as part of the Personalized pREvention of Chronic Diseases (PRECeDI) project. Research of the Alzheimer center Amsterdam is part of the neurodegeneration research program of Amsterdam Neuroscience. The Alzheimer Center Amsterdam is supported by Stichting Alzheimer Nederland and Stichting VUmc fonds. The clinical database structure was developed with funding from Stichting Dioraphte. F.d.L and M.K. are appointed on the NUDAD project, which is funded by NWO‐FCB (project number 057‐14‐004). W.vdF. holds the Pasman chair. F.B. is supported by the NIHR biomedical research center at UCLH. C.T. received grants from the European Commission, the Dutch Research Council (ZonMW), Association of Frontotemporal Dementia/Alzheimer's Drug Discovery Foundation, The Weston Brain Institute, Alzheimer Netherlands. W.F. is recipient of a donation by Stichting Equilibrio, and of a ZonMW Memorabel grant (#733050814). Publisher Copyright: © 2020 The Authors. Alzheimer's & Dementia published by Wiley Periodicals, Inc. on behalf of Alzheimer's Association.
PY - 2021/2
Y1 - 2021/2
N2 - Introduction: Our aim was to study whether systemic metabolites are associated with magnetic resonance imaging (MRI) measures of brain and hippocampal atrophy and white matter hyperintensities (WMH). Methods: We studied associations of 143 plasma-based metabolites with MRI measures of brain and hippocampal atrophy and WMH in three independent cohorts (n = 3962). We meta-analyzed the results of linear regression analyses to determine the association of metabolites with MRI measures. Results: Higher glucose levels and lower levels of three small high density lipoprotein (HDL) particles were associated with brain atrophy. Higher glucose levels were associated with WMH. Discussion: Glucose levels were associated with brain atrophy and WMH, and small HDL particle levels were associated with brain atrophy. Circulating metabolites may aid in developing future intervention trials.
AB - Introduction: Our aim was to study whether systemic metabolites are associated with magnetic resonance imaging (MRI) measures of brain and hippocampal atrophy and white matter hyperintensities (WMH). Methods: We studied associations of 143 plasma-based metabolites with MRI measures of brain and hippocampal atrophy and WMH in three independent cohorts (n = 3962). We meta-analyzed the results of linear regression analyses to determine the association of metabolites with MRI measures. Results: Higher glucose levels and lower levels of three small high density lipoprotein (HDL) particles were associated with brain atrophy. Higher glucose levels were associated with WMH. Discussion: Glucose levels were associated with brain atrophy and WMH, and small HDL particle levels were associated with brain atrophy. Circulating metabolites may aid in developing future intervention trials.
KW - Alzheimer's disease
KW - cholesterol
KW - glucose
KW - lipids
KW - magnetic resonance imaging (MRI)
KW - metabolism
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85090236449&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/32886448
U2 - 10.1002/alz.12180
DO - 10.1002/alz.12180
M3 - Article
C2 - 32886448
VL - 17
SP - 205
EP - 214
JO - Alzheimers & Dementia
JF - Alzheimers & Dementia
SN - 1552-5260
IS - 2
ER -